These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15879857)

  • 1. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.
    Goldfarb DA
    J Urol; 2005 Jun; 173(6):2106-7. PubMed ID: 15879857
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Cyclosporine-sparing' regimen approved.
    Am J Nurs; 2003 Jul; 103(7):64F. PubMed ID: 12877131
    [No Abstract]   [Full Text] [Related]  

  • 5. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.
    Ponticelli C; Salvadori M; Scolari MP; Citterio F; Rigotti P; Veneziano A; Bartezaghi M;
    Transplantation; 2011 May; 91(10):e72-3. PubMed ID: 21540717
    [No Abstract]   [Full Text] [Related]  

  • 6. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients.
    Martínez-Mier G; Méndez-López MT; Estrada-Oros J; Budar-Fernandez LF; Soto-González JI; Méndez-Machado GF; Viñas Dozal JC
    Arch Med Res; 2006 Jul; 37(5):635-8. PubMed ID: 16740435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.
    Thervet E
    Int J Nanomedicine; 2006; 1(3):269-81. PubMed ID: 17717968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine withdrawal in stable renal transplant recipients.
    Mahawar KK
    Transplantation; 2003 Oct; 76(8):1240-1. PubMed ID: 14578763
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New regimen for kidney transplants.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971328
    [No Abstract]   [Full Text] [Related]  

  • 13. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a rationale to combine cyclosporin and sirolimus?
    Kahan BD
    Nephrol Dial Transplant; 1996 Jan; 11(1):21-3. PubMed ID: 8649641
    [No Abstract]   [Full Text] [Related]  

  • 15. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ; Tian YC; Chen YC; Lai BC; Fang JT; Yang CW; Wu MS
    Ren Fail; 2008; 30(3):303-6. PubMed ID: 18350450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunosuppressive agents in kidney transplantation].
    Nishi S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):1-5. PubMed ID: 21370569
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Blanc AS; Di Giambattista F; Dantal J;
    Transplantation; 2009 Jul; 88(1):69-76. PubMed ID: 19584683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preventing rejection, minimizing toxicity: optimized therapy with cyclosporin].
    MMW Fortschr Med; 2002 Jan; 144(3-4):59. PubMed ID: 11862796
    [No Abstract]   [Full Text] [Related]  

  • 19. Steroid sparing in kidney transplantation: changing paradigms, improving outcomes, and remaining questions.
    Augustine JJ; Hricik DE
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1080-9. PubMed ID: 17699329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety.
    Velosa JA; Larson TS; Gloor JM; Stegall MD
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S3-S10. PubMed ID: 11583938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.